Search research articles
Contact Us
Filters
Showing results (11-20 of 19) with videos related to
Page
of 2
Sort By:
You have reached the last page of results.
This site can display upto 19 results.
Clinical Pharmacokinetics
|
December 21, 2024
Population Pharmacokinetics of Epcoritamab Following Subcutaneous Administration in Relapsed or Refractory B Cell Non-Hodgkin Lymphoma
Tommy Li, Leonid Gibiansky, Apurvasena Parikh, et al.
Cancer Chemotherapy and Pharmacology
|
January 27, 2022
Effects of cyclophosphamide related genetic variants on clinical outcomes of adult hematopoietic cell transplant patients
Takuto Takahashi, Rachael Pearson, Qing Cao, et al.
Transplantation and Cellular Therapy
|
May 27, 2021
Higher Fludarabine and Cyclophosphamide Exposures Lead to Worse Outcomes in Reduced-Intensity Conditioning Hematopoietic Cell Transplantation for Adult Hematologic Malignancy
Takuto Takahashi, Aileen Scheibner, Qing Cao, et al.
Clinical Pharmacology and Therapeutics
|
July 7, 2026
Epcoritamab Step-Up Dosing Regimen Selection and Optimization Using Repeated Time-to-Event Modeling for Cytokine Release Syndrome Risk Mitigation
Tommy Li, Andrew Tredennick, Daniel Polhamus, et al.
Translational Research : the Journal of Laboratory and Clinical Medicine
|
April 21, 2016
Personalized fludarabine dosing to reduce nonrelapse mortality in hematopoietic stem-cell transplant recipients receiving reduced intensity conditioning
Kinjal Sanghavi, Anthony Wiseman, Mark N Kirstein, et al.
Plos One
|
May 7, 2015
Differentially expressed gene transcripts using RNA sequencing from the blood of immunosuppressed kidney allograft recipients
Casey Dorr, Baolin Wu, Weihua Guan, et al.
CPT: Pharmacometrics & Systems Pharmacology
|
April 3, 2024
Covariate modeling in pharmacometrics: General points for consideration
Kinjal Sanghavi, Jakob Ribbing, James A Rogers, et al.
JTO Clinical and Research Reports
|
October 24, 2022
BMS-986012, an Anti-Fucosyl-GM1 Monoclonal Antibody as Monotherapy or in Combination With Nivolumab in Relapsed/Refractory SCLC: Results From a First-in-Human Phase 1/2 Study
Quincy Chu, Natasha B Leighl, Veerle Surmont, et al.
Journal for Immunotherapy of Cancer
|
July 7, 2026
Pharmacologic activity, safety, and preliminary efficacy of GEN3009, a CD37-targeting DuoHexaBody, in relapsed or refractory B-cell non-Hodgkin's lymphoma
Farrukh T Awan, Joshua T Gamse, Marije B Overdijk, et al.
Page
of 2
Search research articles
Search
Showing results (11-20 of 19) with videos related to
Sort By:
Page
of 2
You have reached the last page of results.
This site can display upto 19 results.
Clinical Pharmacokinetics
|
December 21, 2024
Population Pharmacokinetics of Epcoritamab Following Subcutaneous Administration in Relapsed or Refractory B Cell Non-Hodgkin Lymphoma
Tommy Li, Leonid Gibiansky, Apurvasena Parikh, et al.
Cancer Chemotherapy and Pharmacology
|
January 27, 2022
Effects of cyclophosphamide related genetic variants on clinical outcomes of adult hematopoietic cell transplant patients
Takuto Takahashi, Rachael Pearson, Qing Cao, et al.
Transplantation and Cellular Therapy
|
May 27, 2021
Higher Fludarabine and Cyclophosphamide Exposures Lead to Worse Outcomes in Reduced-Intensity Conditioning Hematopoietic Cell Transplantation for Adult Hematologic Malignancy
Takuto Takahashi, Aileen Scheibner, Qing Cao, et al.
Clinical Pharmacology and Therapeutics
|
July 7, 2026
Epcoritamab Step-Up Dosing Regimen Selection and Optimization Using Repeated Time-to-Event Modeling for Cytokine Release Syndrome Risk Mitigation
Tommy Li, Andrew Tredennick, Daniel Polhamus, et al.
Translational Research : the Journal of Laboratory and Clinical Medicine
|
April 21, 2016
Personalized fludarabine dosing to reduce nonrelapse mortality in hematopoietic stem-cell transplant recipients receiving reduced intensity conditioning
Kinjal Sanghavi, Anthony Wiseman, Mark N Kirstein, et al.
Plos One
|
May 7, 2015
Differentially expressed gene transcripts using RNA sequencing from the blood of immunosuppressed kidney allograft recipients
Casey Dorr, Baolin Wu, Weihua Guan, et al.
CPT: Pharmacometrics & Systems Pharmacology
|
April 3, 2024
Covariate modeling in pharmacometrics: General points for consideration
Kinjal Sanghavi, Jakob Ribbing, James A Rogers, et al.
JTO Clinical and Research Reports
|
October 24, 2022
BMS-986012, an Anti-Fucosyl-GM1 Monoclonal Antibody as Monotherapy or in Combination With Nivolumab in Relapsed/Refractory SCLC: Results From a First-in-Human Phase 1/2 Study
Quincy Chu, Natasha B Leighl, Veerle Surmont, et al.
Journal for Immunotherapy of Cancer
|
July 7, 2026
Pharmacologic activity, safety, and preliminary efficacy of GEN3009, a CD37-targeting DuoHexaBody, in relapsed or refractory B-cell non-Hodgkin's lymphoma
Farrukh T Awan, Joshua T Gamse, Marije B Overdijk, et al.
Page
of 2